CONNETTIVINA CREAM 15G 2MG/G

CONNETTIVINA 2 MG/G

active ingredients

CONNETTIVINA 2mg/g Cream: 1 g cream contains 2 mg of hyaluronic acid sodium salt. Excipients with known effects: methyl p-hydroxybenzoate and propyl p-hydroxybenzoate. CONNETTIVINA 2 mg/g Gel: 1 g gel contains 2 mg of hyaluronic acid sodium salt. Excipients with known effects: methyl p-hydroxybenzoate and propyl p-hydroxybenzoate. For the full list of excipients, see paragraph 6.1

Excellent

CONNETTIVINA 2 mg/g Polyethyleneglycol cream 400 monostearate - decilic ester of oleic acid - emulsifier wax - glycerol - sorbitol solution 70% - methyl p-hydroxybenzoate - propile p-hydroxybenzoate - aroma (Dalin PH) - purified water CONNETTIVINA 2 mg/g Gel Sorbitol 70% not crystallized - methyl p-hydroxybenzoate - propile p-hydroxybenzoate - Carbomer - sodium hydroxide - purified water

Therapeutic indications

Treatment of abrasions, escoriations, superficial wounds, burns, mild burns and breast ragades. Treatment of localized skin irritations, determined by physical agents such as sun, cold, wind, diaper redness, irritation and dehydration resulting from radiation treatments.

Contraindications

Hypersensitivity to the active ingredient and other substances closely related to the chemical or any of the excipients listed in the paragraph 6.1.

Population

CONNETTIVINA 2 mg/g Cream, CONNETTIVINA 2 mg/g Gel: 2-3 applications per day, evenly covering the whole area concerned.

Conservation

Cream: do not store at temperature above 30°C. Gel: do not store at temperature above 25°C.

Warnings

The use of the product, especially if prolonged, can give rise to phenomena of sensitization. Where this happens, it is necessary to stop the treatment and establish suitable therapy.

Interactions

The association of hyaluronic acid with antibiotics and other local treatments has never given rise to phenomena of interaction. Do not simultaneously use with disinfectants containing quaternary ammonium salts as hyaluronic acid may precipitate in their presence.

Effects

Following application of CONNETTIVINA, local reactions, including allergic reactions were recorded. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address http://www.agenziafarmaco.gov.it/it/responsabili.

Overdosing

No known cases of overdose of CONNETTIVINA.

The drug can be used during pregnancy and nursing.

Source: Farmadati